Grifols Expands Activity in Africa

Grifols, a global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, will establish an intravenous (IV) solutions production plant in Nigeria for Dozie and Dozie's Pharma Nig Ltd., a provider of healthcare products in the country and surrounding region.

When completed in 2024 in southeast Nigeria, the manufacturing installation's initial phase will produce as many as 5.5 million intravenous solutions bags yearly to be used in hospitals and other healthcare institutions in Nigeria and other African countries.

Grifols Engineering, with broad global experience building advanced, specialized production facilities for the healthcare and biotechnology sectors, will design the plant and provide clean rooms and process equipment. Sufficient capacity will be incorporated to enable the doubling of output to meet the expected growth in demand.

"Grifols is extremely pleased to be selected by Dozie and Dozie's Pharma for a state-of-the-art IV solutions manufacturing plant to enhance healthcare delivery in Nigeria and Western Africa," said Daniel Fleta, chief industrial officer, Grifols.

Chidi Dozie, CEO, Dozie and Dozie's Pharma Nig Ltd., said, "This plant is the latest demonstration of our ongoing commitment to provide high-quality medicines and healthcare solutions to meet the growing needs of the region, which currently distributes Grifols plasma-derived therapies.”

Grifols strengthened its presence in Africa when in November 2020 it entered into a deal with the government of Egypt to develop the local market for plasma-derived therapies, including the opening of 20 plasma centers and the construction of a plasma fractionation plant and a purification and fill-and-finish plant. Africa will benefit from this advanced infrastructure aimed at strengthening regional self-sufficiency in hemoderivatives.

The company has also designed and established a plasma collection center and modular laboratories in Liberia as part of efforts to combat Ebola, and is completing an IV solutions plant it designed and equipped in Morocco.